Metropolis Healthcare (METROPOLIS) Stock Overview
Provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for METROPOLIS from our risk checks.
METROPOLIS Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Metropolis Healthcare Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,996.30 |
| 52 Week High | ₹2,318.30 |
| 52 Week Low | ₹1,315.00 |
| Beta | 0.024 |
| 1 Month Change | -9.61% |
| 3 Month Change | 12.58% |
| 1 Year Change | -10.67% |
| 3 Year Change | 30.02% |
| 5 Year Change | 1.49% |
| Change since IPO | 107.98% |
Recent News & Updates
Recent updates
Metropolis Healthcare Limited's (NSE:METROPOLIS) Share Price Matching Investor Opinion
Jul 23
Metropolis Healthcare Limited Just Missed Earnings - But Analysts Have Updated Their Models
May 16Metropolis Healthcare Limited's (NSE:METROPOLIS) P/E Is On The Mark
Apr 15
Expansion Into Specialty Diagnostics Will Strengthen Market Position
Strategic acquisitions and expansion in specialty diagnostics are expected to boost revenue, enhance test offerings, and improve net margins over time.Metropolis Healthcare Limited (NSE:METROPOLIS) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 13Metropolis Healthcare Limited (NSE:METROPOLIS) Just Reported And Analysts Have Been Lifting Their Price Targets
Aug 14Metropolis Healthcare Limited Just Missed EPS By 5.7%: Here's What Analysts Think Will Happen Next
May 24Why Investors Shouldn't Be Surprised By Metropolis Healthcare Limited's (NSE:METROPOLIS) P/E
Mar 28Capital Allocation Trends At Metropolis Healthcare (NSE:METROPOLIS) Aren't Ideal
Jan 13Metropolis Healthcare Limited's (NSE:METROPOLIS) Share Price Matching Investor Opinion
Dec 23Does Metropolis Healthcare (NSE:METROPOLIS) Have A Healthy Balance Sheet?
Sep 08Metropolis Healthcare (NSE:METROPOLIS) Could Be Struggling To Allocate Capital
Jun 20Metropolis Healthcare (NSE:METROPOLIS) Might Be Having Difficulty Using Its Capital Effectively
Mar 14Metropolis Healthcare's (NSE:METROPOLIS) Dividend Will Be ₹8.00
Feb 13Metropolis Healthcare Limited's (NSE:METROPOLIS) Intrinsic Value Is Potentially 25% Below Its Share Price
Sep 25Is Metropolis Healthcare (NSE:METROPOLIS) A Risky Investment?
Sep 10Metropolis Healthcare (NSE:METROPOLIS) Has A Rock Solid Balance Sheet
Jun 07Capital Investments At Metropolis Healthcare (NSE:METROPOLIS) Point To A Promising Future
May 16Is Now The Time To Put Metropolis Healthcare (NSE:METROPOLIS) On Your Watchlist?
Mar 17Capital Investments At Metropolis Healthcare (NSE:METROPOLIS) Point To A Promising Future
Jan 29Do Metropolis Healthcare's (NSE:METROPOLIS) Earnings Warrant Your Attention?
Dec 14Metropolis Healthcare (NSE:METROPOLIS) Looks To Prolong Its Impressive Returns
Oct 12Shareholder Returns
| METROPOLIS | IN Healthcare | IN Market | |
|---|---|---|---|
| 7D | -0.9% | -0.4% | 1.5% |
| 1Y | -10.7% | 21.4% | -4.7% |
Return vs Industry: METROPOLIS underperformed the Indian Healthcare industry which returned 20.8% over the past year.
Return vs Market: METROPOLIS underperformed the Indian Market which returned -6% over the past year.
Price Volatility
| METROPOLIS volatility | |
|---|---|
| METROPOLIS Average Weekly Movement | 5.4% |
| Healthcare Industry Average Movement | 4.9% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.3% |
| 10% least volatile stocks in IN Market | 3.2% |
Stable Share Price: METROPOLIS has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: METROPOLIS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 4,823 | Surendran Chemmenkotil | www.metropolisindia.com |
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinical trial research, hospital lab management, and home collection services, as well as profiles, blood tests, and soft radiology services. It also provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, youth, and corporates.
Metropolis Healthcare Limited Fundamentals Summary
| METROPOLIS fundamental statistics | |
|---|---|
| Market cap | ₹103.42b |
| Earnings (TTM) | ₹1.52b |
| Revenue (TTM) | ₹14.04b |
Is METROPOLIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| METROPOLIS income statement (TTM) | |
|---|---|
| Revenue | ₹14.04b |
| Cost of Revenue | ₹3.19b |
| Gross Profit | ₹10.85b |
| Other Expenses | ₹9.33b |
| Earnings | ₹1.52b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 29.36 |
| Gross Margin | 77.29% |
| Net Profit Margin | 10.83% |
| Debt/Equity Ratio | 15.3% |
How did METROPOLIS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 02:31 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Metropolis Healthcare Limited is covered by 42 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ashwin Mehta | Ambit Capital |
| Nitin Bhasin | Ambit Capital |
| Prashant Nair | Ambit Capital |